Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.17
DNPUF's Cash to Debt is ranked higher than
70% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. DNPUF: 1.17 )
DNPUF' s 10-Year Cash to Debt Range
Min: 0.39   Max: No Debt
Current: 1.17

Equity to Asset 0.62
DNPUF's Equity to Asset is ranked higher than
71% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. DNPUF: 0.62 )
DNPUF' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.85
Current: 0.62

0.51
0.85
Interest Coverage 41.85
DNPUF's Interest Coverage is ranked higher than
64% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. DNPUF: 41.85 )
DNPUF' s 10-Year Interest Coverage Range
Min: 16.13   Max: 335.12
Current: 41.85

16.13
335.12
F-Score: 9
Z-Score: 3.16
M-Score: -3.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.78
DNPUF's Operating margin (%) is ranked higher than
77% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.96 vs. DNPUF: 10.78 )
DNPUF' s 10-Year Operating margin (%) Range
Min: 5.82   Max: 17.44
Current: 10.78

5.82
17.44
Net-margin (%) 5.42
DNPUF's Net-margin (%) is ranked higher than
70% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. DNPUF: 5.42 )
DNPUF' s 10-Year Net-margin (%) Range
Min: 2.46   Max: 9.69
Current: 5.42

2.46
9.69
ROE (%) 5.39
DNPUF's ROE (%) is ranked higher than
70% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. DNPUF: 5.39 )
DNPUF' s 10-Year ROE (%) Range
Min: 2.68   Max: 8.21
Current: 5.39

2.68
8.21
ROA (%) 3.26
DNPUF's ROA (%) is ranked higher than
71% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. DNPUF: 3.26 )
DNPUF' s 10-Year ROA (%) Range
Min: 1.5   Max: 6.54
Current: 3.26

1.5
6.54
ROC (Joel Greenblatt) (%) 20.55
DNPUF's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. DNPUF: 20.55 )
DNPUF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.38   Max: 34.77
Current: 20.55

10.38
34.77
Revenue Growth (%) 0.70
DNPUF's Revenue Growth (%) is ranked higher than
62% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. DNPUF: 0.70 )
DNPUF' s 10-Year Revenue Growth (%) Range
Min: -14.4   Max: 12.9
Current: 0.7

-14.4
12.9
EBITDA Growth (%) -4.40
DNPUF's EBITDA Growth (%) is ranked higher than
63% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. DNPUF: -4.40 )
DNPUF' s 10-Year EBITDA Growth (%) Range
Min: -4.4   Max: 10.2
Current: -4.4

-4.4
10.2
EPS Growth (%) 6.10
DNPUF's EPS Growth (%) is ranked higher than
74% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. DNPUF: 6.10 )
DNPUF' s 10-Year EPS Growth (%) Range
Min: -24.4   Max: 15.4
Current: 6.1

-24.4
15.4
» DNPUF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with DNPUF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.50
DNPUF's P/E(ttm) is ranked higher than
87% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. DNPUF: 23.50 )
DNPUF' s 10-Year P/E(ttm) Range
Min: 11.92   Max: 83.74
Current: 23.5

11.92
83.74
P/B 1.25
DNPUF's P/B is ranked higher than
91% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.26 vs. DNPUF: 1.25 )
DNPUF' s 10-Year P/B Range
Min: 0.73   Max: 2.03
Current: 1.25

0.73
2.03
P/S 1.28
DNPUF's P/S is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. DNPUF: 1.28 )
DNPUF' s 10-Year P/S Range
Min: 0.69   Max: 5.77
Current: 1.28

0.69
5.77
EV-to-EBIT 11.00
DNPUF's EV-to-EBIT is ranked higher than
93% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.26 vs. DNPUF: 11.00 )
DNPUF' s 10-Year EV-to-EBIT Range
Min: 8.7   Max: 46.5
Current: 11

8.7
46.5
PEG 18.08
DNPUF's PEG is ranked higher than
81% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DNPUF: 18.08 )
DNPUF' s 10-Year PEG Range
Min: 1.54   Max: 4.11
Current: 18.08

1.54
4.11
Shiller P/E 29.18
DNPUF's Shiller P/E is ranked higher than
86% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 97.53 vs. DNPUF: 29.18 )
DNPUF' s 10-Year Shiller P/E Range
Min: 26.84   Max: 45.22
Current: 29.18

26.84
45.22
Current Ratio 2.97
DNPUF's Current Ratio is ranked higher than
78% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. DNPUF: 2.97 )
DNPUF' s 10-Year Current Ratio Range
Min: 1.06   Max: 5.77
Current: 2.97

1.06
5.77
Quick Ratio 2.44
DNPUF's Quick Ratio is ranked higher than
78% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. DNPUF: 2.44 )
DNPUF' s 10-Year Quick Ratio Range
Min: 0.84   Max: 4.68
Current: 2.44

0.84
4.68

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.16
DNPUF's Dividend Yield is ranked lower than
56% of the 493 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. DNPUF: 1.16 )
DNPUF' s 10-Year Dividend Yield Range
Min: 0.82   Max: 2.53
Current: 1.16

0.82
2.53
Dividend Payout 0.29
DNPUF's Dividend Payout is ranked higher than
82% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.21 vs. DNPUF: 0.29 )
DNPUF' s 10-Year Dividend Payout Range
Min: 0.61   Max: 3.16
Current: 0.29

0.61
3.16
Dividend growth (3y) -2.00
DNPUF's Dividend growth (3y) is ranked higher than
74% of the 360 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. DNPUF: -2.00 )
DNPUF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 21.6
Current: -2

0
21.6
Yield on cost (5-Year) 1.07
DNPUF's Yield on cost (5-Year) is ranked lower than
60% of the 500 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. DNPUF: 1.07 )
DNPUF' s 10-Year Yield on cost (5-Year) Range
Min: 0.73   Max: 2.25
Current: 1.07

0.73
2.25

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.03
DNPUF's Price/Tangible Book is ranked higher than
87% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.76 vs. DNPUF: 2.03 )
DNPUF' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 3.44
Current: 2.03

1.02
3.44
Price/DCF (Projected) 0.59
DNPUF's Price/DCF (Projected) is ranked higher than
99% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.71 vs. DNPUF: 0.59 )
DNPUF' s 10-Year Price/DCF (Projected) Range
Min: 0.55   Max: 0.83
Current: 0.59

0.55
0.83
Price/Median PS Value 1.01
DNPUF's Price/Median PS Value is ranked higher than
84% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.24 vs. DNPUF: 1.01 )
DNPUF' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 4.23
Current: 1.01

0.62
4.23
Price/Peter Lynch Fair Value 2.20
DNPUF's Price/Peter Lynch Fair Value is ranked higher than
90% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DNPUF: 2.20 )
DNPUF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 2.06   Max: 3.72
Current: 2.2

2.06
3.72
Price/Graham Number 1.45
DNPUF's Price/Graham Number is ranked higher than
90% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.69 vs. DNPUF: 1.45 )
DNPUF' s 10-Year Price/Graham Number Range
Min: 0.96   Max: 3.26
Current: 1.45

0.96
3.26
Earnings Yield (Greenblatt) 9.10
DNPUF's Earnings Yield (Greenblatt) is ranked higher than
89% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. DNPUF: 9.10 )
DNPUF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 11.5
Current: 9.1

2.1
11.5
Forward Rate of Return (Yacktman) 18.95
DNPUF's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. DNPUF: 18.95 )
DNPUF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 18.3   Max: 42.6
Current: 18.95

18.3
42.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:4506.Japan, DPM.Germany
Dainippon Sumitomo Pharma Co., Ltd. is engaged in the manufacture, sale, purchase, and import, export of pharmaceuticals, veterinary products, food additives, industrial chemicals, and other chemical products, etc.
» More Articles for OTCPK:DNPUF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK